^
    Back
    Association details:
    Biomarker:BCR-ABL1 F359
    Cancer:Leukemia
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) +
    Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ASH 2019
    Title:

    Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants

    Published date:
    11/06/2019
    Excerpt:
    Asciminib potently inhibited the proliferation of most imatinib-resistant BCR-ABL1 point mutations tested, with the notable exception of substitutions at position F359, which conferred high levels of resistance.
    DOI:
    https://doi.org/10.1182/blood-2019-131781